<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36813419</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-1942</ISSN><JournalIssue CitedMedium="Internet"><Volume>52</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Gastroenterology clinics of North America</Title><ISOAbbreviation>Gastroenterol Clin North Am</ISOAbbreviation></Journal><ArticleTitle>COVID-19 and Inflammatory Bowel Disease.</ArticleTitle><Pagination><StartPage>103</StartPage><EndPage>113</EndPage><MedlinePgn>103-113</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.gtc.2022.10.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0889-8553(22)00084-X</ELocationID><Abstract><AbstractText>The COVID-19 pandemic caused by the SARS-CoV-2 virus represents an unprecedented global health crisis. Safe and effective vaccines were rapidly developed and deployed that reduced COVID-19-related severe disease, hospitalization, and death. Patients with inflammatory bowel disease are not at increased risk of severe disease or death from COVID-19, and data from large cohorts of patients with inflammatory bowel disease demonstrate that COVID-19 vaccination is safe and effective. Ongoing research is clarifying the long-term impact of SARS-CoV-2 infection on patients with inflammatory bowel disease, long-term immune responses to COVID-19 vaccination, and optimal timing for repeated COVID-19 vaccination doses.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Summa</LastName><ForeName>Keith C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Department of Medicine, Northwestern University Feinberg School of Medicine, 676 North Saint Clair Street, Suite 1400, Chicago, IL 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanauer</LastName><ForeName>Stephen B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Department of Medicine, Northwestern University Feinberg School of Medicine, 676 North Saint Clair Street, Suite 1400, Chicago, IL 60611, USA. Electronic address: shanauer@northwestern.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Gastroenterol Clin North Am</MedlineTA><NlmUniqueID>8706257</NlmUniqueID><ISSNLinking>0889-8553</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015212" MajorTopicYN="Y">Inflammatory Bowel Diseases</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID vaccination</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Crohn disease</Keyword><Keyword MajorTopicYN="N">Immunosuppression</Keyword><Keyword MajorTopicYN="N">Inflammatory bowel disease</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Ulcerative colitis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>22</Day><Hour>20</Hour><Minute>58</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36813419</ArticleId><ArticleId IdType="pmc">PMC9618438</ArticleId><ArticleId IdType="doi">10.1016/j.gtc.2022.10.005</ArticleId><ArticleId IdType="pii">S0889-8553(22)00084-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shivshankar P., Karmouty-Quintana H., Mills T., et al. SARS-CoV-2 infection: host response. Immunity, Ther Targets Inflamm. 2022;45(4):1430&#x2013;1449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8940980</ArticleId><ArticleId IdType="pubmed">35320469</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson C.B., Farzan M., Chen B., et al. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 2022;23(1):3&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8491763</ArticleId><ArticleId IdType="pubmed">34611326</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao F., Tang M., Zheng X., et al. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology. 2020;158(6):1831&#x2013;1833 e3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7130181</ArticleId><ArticleId IdType="pubmed">32142773</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou X., Chen K., Zou J., et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020;14(2):185&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7088738</ArticleId><ArticleId IdType="pubmed">32170560</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan L., Mu M., Yang P., et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol. 2020;115(5):766&#x2013;773.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7172492</ArticleId><ArticleId IdType="pubmed">32287140</ArticleId></ArticleIdList></Reference><Reference><Citation>Han C., Duan C., Zhang S., et al. Digestive symptoms in COVID-19 patients with mild disease severity: clinical presentation, stool viral RNA testing, and outcomes. Am J Gastroenterol. 2020;115(6):916&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7172493</ArticleId><ArticleId IdType="pubmed">32301761</ArticleId></ArticleIdList></Reference><Reference><Citation>Holshue M.L., DeBolt C., Lindquist S., et al. First case of 2019 novel coronavirus in the United States. N&#xa0;Engl J Med. 2020;382(10):929&#x2013;936.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092802</ArticleId><ArticleId IdType="pubmed">32004427</ArticleId></ArticleIdList></Reference><Reference><Citation>Solitano V., Facciorusso A., Jess T., et al. Comparative risk of serious infections with biologic agents and oral small molecules in inflammatory bowel diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022 doi: 10.1016/j.cgh.2022.07.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2022.07.032</ArticleId><ArticleId IdType="pubmed">35944832</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S., Facciorusso A., Dulai P.S., et al. Comparative risk of serious infections with biologic and/or immunosuppressive therapy in patients with inflammatory bowel diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2020;18(1):69&#x2013;81 e3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8011651</ArticleId><ArticleId IdType="pubmed">30876964</ArticleId></ArticleIdList></Reference><Reference><Citation>Aziz M., Fatima R., Haghbin H., et al. The incidence and outcomes of COVID-19 in IBD patients: a rapid review and meta-analysis. Inflamm Bowel Dis. 2020;26(10):e132&#x2013;e133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7337801</ArticleId><ArticleId IdType="pubmed">32619003</ArticleId></ArticleIdList></Reference><Reference><Citation>Allocca M., Chaparro M., Gonzalez H.A., et al. Patients with inflammatory bowel disease are not at increased risk of COVID-19: a large multinational cohort study. J&#xa0;Clin Med. 2020;9(11) doi: 10.3390/jcm9113533.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9113533</ArticleId><ArticleId IdType="pmc">PMC7693947</ArticleId><ArticleId IdType="pubmed">33142843</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukin D.J., Kumar A., Hajifathalian K., et al. Baseline disease activity and steroid therapy stratify risk of COVID-19 in patients with inflammatory bowel disease. Gastroenterology. 2020;159(4):1541&#x2013;1544 e2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7256492</ArticleId><ArticleId IdType="pubmed">32479824</ArticleId></ArticleIdList></Reference><Reference><Citation>Macaluso F.S., Giuliano A., Fries W., et al. Severe activity of inflammatory bowel disease is a risk factor for severe COVID-19. Inflamm Bowel Dis. 2022 doi: 10.1093/ibd/izac064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ibd/izac064</ArticleId><ArticleId IdType="pmc">PMC9383704</ArticleId><ArticleId IdType="pubmed">35385102</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner E.J., Ungaro R.C., Gearry R.B., et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology. 2020;159(2):481&#x2013;491 e3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233252</ArticleId><ArticleId IdType="pubmed">32425234</ArticleId></ArticleIdList></Reference><Reference><Citation>Ungaro R.C., Brenner E.J., Gearry R.B., et al. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut. 2021;70(4):725&#x2013;732.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8136807</ArticleId><ArticleId IdType="pubmed">33082265</ArticleId></ArticleIdList></Reference><Reference><Citation>Ungaro R.C., Brenner E.J., Agrawal M., et al. Impact of medications on COVID-19 outcomes in inflammatory bowel disease: analysis of more than 6000 patients from an international registry. Gastroenterology. 2022;162(1):316&#x2013;319 e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8437703</ArticleId><ArticleId IdType="pubmed">34529987</ArticleId></ArticleIdList></Reference><Reference><Citation>Attauabi M., Seidelin J., Burisch J., et al. Association between 5-aminosalicylates in patients with IBD and risk of severe COVID-19: an artefactual result of research methodology? Gut. 2021;70(10):2020&#x2013;2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">33658323</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal M., Brenner E.J., Zhang X., et al. Characteristics and outcomes of IBD patients with COVID-19 on tofacitinib therapy in the SECURE-IBD Registry. Inflamm Bowel Dis. 2021;27(4):585&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7799122</ArticleId><ArticleId IdType="pubmed">33325523</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer A., Prinz C., Fichtner F., et al. Janus kinase inhibitors for the treatment of COVID-19. Cochrane Database Syst Rev. 2022;6:CD015209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9190191</ArticleId><ArticleId IdType="pubmed">35695334</ArticleId></ArticleIdList></Reference><Reference><Citation>Castanares-Zapatero D., Chalon P., Kohn L., et al. Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med. 2022;54(1):1473&#x2013;1487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9132392</ArticleId><ArticleId IdType="pubmed">35594336</ArticleId></ArticleIdList></Reference><Reference><Citation>Meringer H., Mehandru S. Gastrointestinal post-acute COVID-19 syndrome. Nat Rev Gastroenterol Hepatol. 2022;19(6):345&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8981882</ArticleId><ArticleId IdType="pubmed">35383321</ArticleId></ArticleIdList></Reference><Reference><Citation>Freedberg D.E., Chang L. Gastrointestinal symptoms in COVID-19: the long and the short of it. Curr Opin Gastroenterol. 2022;38(6):555&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">36165028</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhury A., Tariq R., Jena A., et al. Gastrointestinal manifestations of long COVID: a systematic review and meta-analysis. Therap Adv Gastroenterol. 2022;15 17562848221118403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9393939</ArticleId><ArticleId IdType="pubmed">36004306</ArticleId></ArticleIdList></Reference><Reference><Citation>Zollner A., Koch R., Jukic A., et al. Postacute COVID-19 is characterized by gut viral antigen persistence in inflammatory bowel diseases. Gastroenterology. 2022 doi: 10.1053/j.gastro.2022.04.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2022.04.037</ArticleId><ArticleId IdType="pmc">PMC9057012</ArticleId><ArticleId IdType="pubmed">35508284</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C., Wang Z., Lorenzi J.C.C., et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591(7851):639&#x2013;644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaver K.N., Zhang X., Dai X., et al. Impact of SARS-CoV-2 vaccination on inflammatory bowel disease activity and development of vaccine-related adverse events: results from PREVENT-COVID. Inflamm Bowel Dis. 2021 doi: 10.1093/ibd/izab302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ibd/izab302</ArticleId><ArticleId IdType="pmc">PMC8822409</ArticleId><ArticleId IdType="pubmed">34871388</ArticleId></ArticleIdList></Reference><Reference><Citation>Jena A., James D., Singh A.K., et al. Effectiveness and durability of COVID-19 vaccination in 9447 patients with IBD: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022;20(7):1456&#x2013;1479 e18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8856753</ArticleId><ArticleId IdType="pubmed">35189387</ArticleId></ArticleIdList></Reference><Reference><Citation>James D., Jena A., Bharath P.N., et al. Safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease: a systematic review and meta-analysis. Dig Liver Dis. 2022;54(6):713&#x2013;721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8938236</ArticleId><ArticleId IdType="pubmed">35382972</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D., Debbas P., Cheng S., et al. Post-vaccination symptoms after a third dose of mRNA SARS-CoV-2 vaccination in patients with inflammatory bowel disease. medRxiv. 2021 doi: 10.1101/2021.12.05.21266089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.12.05.21266089</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Chanchlani N., Lin S., Chee D., et al. Adalimumab and infliximab impair SARS-CoV-2 antibody responses: results from a therapeutic drug monitoring study in 11 422 biologic-treated patients. J&#xa0;Crohns Colitis. 2022;16(3):389&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8499950</ArticleId><ArticleId IdType="pubmed">34473254</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy N.A., Goodhand J.R., Bewshea C., et al. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut. 2021;70(5):865&#x2013;875.</Citation><ArticleIdList><ArticleId IdType="pubmed">33753421</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy N.A., Lin S., Goodhand J.R., et al. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut. 2021;70(10):1884&#x2013;1893.</Citation><ArticleIdList><ArticleId IdType="pubmed">33903149</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel C.A., Melmed G.Y., McGovern D.P., et al. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. Gut. 2021;70(4):635&#x2013;640.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7818789</ArticleId><ArticleId IdType="pubmed">33472895</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander J.L., Moran G.W., Gaya D.R., et al. SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. Lancet Gastroenterol Hepatol. 2021;6(3):218&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7834976</ArticleId><ArticleId IdType="pubmed">33508241</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>